<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02956720</url>
  </required_header>
  <id_info>
    <org_study_id>DHF21321</org_study_id>
    <nct_id>NCT02956720</nct_id>
  </id_info>
  <brief_title>UltraShape Power in Combination With U-sculpt-n Transducer</brief_title>
  <official_title>Clinical Evaluation of UltraShape Power System in Conjunction With the U-Sculpt-N Transducer for Non-invasive Circumference Reduction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Syneron Candela</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Syneron Candela</source>
  <brief_summary>
    <textblock>
      Prospective, open label, self - controlled, single arm, clinical study to assess the
      performance of the UltraShape Power using the U-Sculpt-N on outer thigh and/or flank for
      circumference reduction versus self-control.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>prospective, single arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Outer thigh circumference reduction</measure>
    <time_frame>up to 24 week</time_frame>
    <description>To evaluate circumference reduction of outer thigh post treatment with UltraShape Power device used with the U-Sculpt-N transducer versus control side.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-related adverse events</measure>
    <time_frame>up to 24 week</time_frame>
    <description>The frequency and severity of all treatment-related adverse events during and after using the UltraShape Power device used with the U-Sculpt-N transducer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject satisfaction questionnaire</measure>
    <time_frame>up to 24 week</time_frame>
    <description>The assessment of subject satisfaction with treatment will be recorded during relevant visits (starting following the first treatment) using a 5-point Likert scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Circumference Reduction</condition>
  <arm_group>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>UltraShape Power</intervention_name>
    <description>non-invasive body contouring procedure</description>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject ≥18 and ≤60 years of age at the time of enrollment

          2. Fat thickness of at least 1.5 cm in the outer thigh and/or flank (measured by
             calibrated caliper)

          3. For women of child-bearing potential: negative urine pregnancy test

          4. General good health confirmed by medical history and skin examination of the treated
             area

          5. Subject understands the study requirements and the treatment procedures and provides
             written Informed Consent before any study-specific tests or procedures are performed.

        Exclusion Criteria:

          1. History of un-balanced hypertension, ischemic heart disease, valvular heart disease,
             congestive heart failure, pacemaker/defibrillator

          2. Current hyperlipidemia, diabetes mellitus, hepatitis, liver disease, HIV positive
             status, blood coagulopathy or excessive bleeding, autoimmune or connective tissue
             disease

          3. Having a permanent implant in the treated area, such as metal plates, or an injected
             chemical substance such as silicone

          4. Previous liposuction in the treatment areas within 12 months

          5. History of skin disease in the treatment area, known tendency to form keloids or poor
             wound healing

          6. Abnormal kidney, liver or coagulation functions, abnormal lipid profile or blood count
             within the last 3 months

          7. Childbirth within the last 12 months or women who are breastfeeding a child
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ketty Shkolnik, Ph.D.</last_name>
    <phone>+972-73-2442268</phone>
    <email>kettys@syneron-candela.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beit Noah</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronen Glesinger, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2016</study_first_submitted>
  <study_first_submitted_qc>November 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2016</study_first_posted>
  <last_update_submitted>July 30, 2017</last_update_submitted>
  <last_update_submitted_qc>July 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Syneron Candela</investigator_affiliation>
    <investigator_full_name>Ronen Glesinger</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

